Exceptional Response to Trastuzumab Deruxtecan in a Patient With Recurrent Ovarian Clear Cell Carcinoma With Human Epidermal Growth Factor Receptor 2 Expression.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 38905574.
- Also identified by DOI 10.1200/PO.23.00686 and PMC identifier 11371105.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
Case report of a HER2-expressed ovarian clear cell carcinoma with exceptional response to trastuzumab deruxtecan.
Medical subject headings
- Trastuzumab
- Ovarian Neoplasms
- Erb-b2 Receptor Tyrosine Kinases
- Neoplasm Recurrence, Local